Equillium, Inc. (NASDAQ:EQ) Short Interest Up 620.6% in February

Equillium, Inc. (NASDAQ:EQ) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 672,300 shares, an increase of 620.6% from the January 31st total of 93,300 shares. Currently, 3.9% of the company’s shares are short sold. Based on an average daily trading volume, of 771,000 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Equillium stock. Takeda Pharmaceutical Co. Ltd. bought a new position in shares of Equillium, Inc. (NASDAQ:EQ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium comprises about 5.2% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 4th largest position. Takeda Pharmaceutical Co. Ltd. owned 5.15% of Equillium at the end of the most recent reporting period. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Stock Performance

EQ traded down $0.00 during trading on Thursday, reaching $0.76. 44,859 shares of the stock were exchanged, compared to its average volume of 1,233,462. Equillium has a twelve month low of $0.49 and a twelve month high of $2.99. The stock has a market cap of $27.05 million, a P/E ratio of -5.45 and a beta of 1.79. The stock’s 50 day moving average price is $0.74 and its two-hundred day moving average price is $0.82.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.